Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study.
A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).
Fiorentini
G
G
Department of Oncology, "S Giuseppe" Hospital, Empoli (Florence), Italy. oncologiaempoli@usl11.toscana.it
Poddie
D B
DB
Cantore
M
M
Rossi
S
S
Tumolo
S
S
Dentico
P
P
Bernardeschi
P
P
Guadagni
S
S
Rossi
G
G
Valori
V M
VM
De Simone
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000473:pathology*; D015251:Epirubicin / Q000008:administration & dosage; D005374:Filtration; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D016685:Mitomycin / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate
D015251:Epirubicin; D016685:Mitomycin